Sign in

CIK 0001842295

  • Non-accelerated filer
  • Emerging growth company

Maze Therapeutics, Inc.

Sign in to watch
Ticker
MAZE
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 650-850-5070
Business address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Planned sale Chief Executive Officer sold 34,501 shares at an average $26.73 ($922,315)
  2. 4 Planned sale CSBO sold 7,500 shares at an average $27.34 ($205,031)
  3. 4 Planned sale President, R&D & CMO sold 14,609 shares at an average $29.90 ($436,864)
  4. 4 Planned sale Chief Executive Officer sold 34,501 shares at an average $29.98 ($1,034,253)
  5. 4 Planned sale CSBO sold 7,500 shares at $28.02 ($210,150)
  6. 4 Planned sale Chief Executive Officer sold 27,858 shares at an average $26.04 ($725,495)
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Planned sale Chief Executive Officer sold 6,643 shares at an average $26.20 ($174,048)
  14. 4 Planned sale President, R&D & CMO sold 14,853 shares at an average $25.66 ($381,112)
  15. 4 Planned sale CSBO sold 7,500 shares at $26.34 ($197,554)
  16. 4 Planned sale Chief Executive Officer sold 32,564 shares at an average $26.01 ($847,048)
  17. 4 Planned sale Chief Executive Officer sold 1,938 shares at $26.00 ($50,388)
  18. 4 Planned sale President, R&D & CMO sold 15,000 shares at $26.22 ($393,354)
  19. 4 Exercise or conversion CSBO acquired 14,305 shares (option exercise)
  20. 4 Gift Director gave 7,422 shares (gift)

Page 2 of 6 · 108 filings